- Home
- BIDU vs ARGX Comparison
BIDU vs ARGX Comparison
Compare BIDU & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIDU | ARGX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | China | Netherlands |
| Employees | 33500 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 42.9B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BIDU | ARGX |
|---|---|---|
| Price | $111.80 | $876.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | $154.38 | ★ $1,008.56 |
| AVG Volume (30 Days) | ★ 2.2M | 280.5K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.11 | $44.39 |
| Revenue Next Year | $7.44 | $20.84 |
| P/E Ratio | $42.45 | ★ $33.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.64 | $510.06 |
| 52 Week High | $165.30 | $934.62 |
Technical Indicators
Market Signals| Indicator | BIDU | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 57.57 |
| Support Level | $107.10 | $810.49 |
| Resistance Level | $130.66 | $881.89 |
| Average True Range (ATR) | 4.14 | 25.95 |
| MACD | -1.81 | 1.37 |
| Stochastic Oscillator | 4.42 | 71.22 |
Price Performance
Historical ComparisonAbout BIDU Baidu Inc. ADS
Most of Baidu's revenue comes from Baidu core, with the rest coming from video-streaming subsidiary iQiyi. The firm's main businesses include online marketing services from its search engine, AI cloud infrastructure, AI applications, AI marketing, and autonomous driving.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.